Myrtle S. Potter
Known title: DirectorCIK: 0001214130
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Analysts Reassess AI Demand, Lift Ginkgo Bioworks Fair Value. Analysts have updated their view on Ginkgo Bioworks, raising its fair value after a renewed focus on AI applications in biotechnology. TD Cowen kept a hold rating but lifted its target price to $11, reflecting optimism about the company’s growth prospects. The stock has been trading below its 52‑week low and fell more than the broader market, suggesting investors are still cautious.
Transaction History
| GH | ▼ Sell | Open Market | 1,556 | $204K | 6/22/2026 | View on chart |
| GH | ▲ Buy | Option Exercise | 4,203 | $0 | 6/17/2026 | View on chart |
| GH | ▼ Sell | Open Market | 26 | $2K | 10/17/2025 | View on chart |
| GH | ▲ Buy | Option Exercise | 69 | $0 | 10/15/2025 | View on chart |
| GH | ▼ Sell | Open Market | 26 | $1K | 9/17/2025 | View on chart |
| GH | ▲ Buy | Option Exercise | 68 | $0 | 9/15/2025 | View on chart |
| GH | ▼ Sell | Open Market | 26 | $2K | 8/19/2025 | View on chart |
| GH | ▲ Buy | Option Exercise | 69 | $0 | 8/15/2025 | View on chart |
| GH | ▼ Sell | Open Market | 26 | $1K | 7/17/2025 | View on chart |
| GH | ▲ Buy | Option Exercise | 68 | $0 | 7/15/2025 | View on chart |
| GH | ▼ Sell | Open Market | 26 | $1K | 6/18/2025 | View on chart |
| GH | ▼ Sell | Open Market | 2,626 | $131K | 6/16/2025 | View on chart |
| GH | ▲ Buy | Option Exercise | 69 | $0 | 6/15/2025 | View on chart |
| GH | ▲ Buy | Option Exercise | 6,674 | $0 | 6/12/2025 | View on chart |
| DNA | ▲ Buy | Option Exercise | 10,822 | — | 6/11/2025 | View on chart |
| GH | ▲ Buy | Option Exercise | 68 | $0 | 5/15/2025 | View on chart |
| GH | ▲ Buy | Option Exercise | 68 | $0 | 4/15/2025 | View on chart |
| GH | ▲ Buy | Option Exercise | 69 | $0 | 3/15/2025 | View on chart |
| GH | ▲ Buy | Option Exercise | 68 | $0 | 2/15/2025 | View on chart |
| GH | ▲ Buy | Option Exercise | 68 | $0 | 1/15/2025 | View on chart |
| GH | ▲ Buy | Option Exercise | 69 | $0 | 12/15/2024 | View on chart |
| GH | ▲ Buy | Option Exercise | 68 | $0 | 11/15/2024 | View on chart |
| GH | ▲ Buy | Option Exercise | 69 | $0 | 10/15/2024 | View on chart |
| GH | ▲ Buy | Option Exercise | 68 | $0 | 9/15/2024 | View on chart |
| GH | ▲ Buy | Option Exercise | 68 | $0 | 8/15/2024 | View on chart |
| GH | ▲ Buy | Option Exercise | 69 | $0 | 7/15/2024 | View on chart |
| GH | ▲ Buy | Option Exercise | 68 | $0 | 6/15/2024 | View on chart |
| GH | ▲ Buy | Option Exercise | 5,592 | $0 | 6/12/2024 | View on chart |
| GH | ▲ Buy | Option Exercise | 69 | $0 | 5/15/2024 | View on chart |
| GH | ▲ Buy | Option Exercise | 68 | $0 | 4/15/2024 | View on chart |
| GH | ▲ Buy | Option Exercise | 68 | $0 | 3/15/2024 | View on chart |
| GH | ▲ Buy | Option Exercise | 69 | $0 | 2/15/2024 | View on chart |
| GH | ▲ Buy | Option Exercise | 68 | $0 | 1/15/2024 | View on chart |
| GH | ▲ Buy | Option Exercise | 69 | $0 | 12/15/2023 | View on chart |
| GH | ▲ Buy | Option Exercise | 68 | $0 | 11/15/2023 | View on chart |
| GH | ▲ Buy | Option Exercise | 68 | $0 | 10/15/2023 | View on chart |
| GH | ▲ Buy | Option Exercise | 69 | $0 | 9/15/2023 | View on chart |
| GH | ▲ Buy | Option Exercise | 68 | $0 | 8/15/2023 | View on chart |
| GH | ▲ Buy | Option Exercise | 69 | $0 | 7/15/2023 | View on chart |
| GH | ▲ Buy | Option Exercise | 68 | $0 | 6/15/2023 | View on chart |
| GH | ▲ Buy | Option Exercise | 5,531 | $0 | 6/14/2023 | View on chart |
| GH | ▲ Buy | Option Exercise | 68 | $0 | 5/15/2023 | View on chart |
| GH | ▲ Buy | Option Exercise | 69 | $0 | 4/15/2023 | View on chart |
| GH | ▲ Buy | Grant | 68 | $0 | 3/15/2023 | View on chart |
| GH | ▲ Buy | Grant | 69 | $0 | 2/15/2023 | View on chart |
| GH | ▲ Buy | Option Exercise | 68 | $0 | 1/15/2023 | View on chart |
| GH | ▲ Buy | Grant | 68 | $0 | 12/15/2022 | View on chart |
| GH | ▲ Buy | Option Exercise | 69 | $0 | 11/15/2022 | View on chart |
| GH | ▲ Buy | Option Exercise | 820 | $0 | 10/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Guardant Health Wins Patent Ruling, Morgan Stanley Lifts Target
Guardant Health secured a favorable decision from the U.S. Patent Trial and Appeal Board, which rejected a challenge to its core duplex sequencing patent. This legal win supports the company's position in the growing liquid biopsy market. Additionally, Morgan Stanley maintained an Overweight rating and raised its price target to $200, citing strong fundamentals in the diagnostics sector.
Guardant Health Wins Patent Ruling, Morgan Stanley Lifts Target. Guardant Health secured a favorable decision from the U.S. Patent Trial and Appeal Board, which rejected a challenge to its core duplex sequencing patent. This legal win supports the company's position in the growing liquid biopsy market. Additionally, Morgan Stanley maintained an Overweight rating and raised its price target to $200, citing strong fundamentals in the diagnostics sector.